Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 Mutation
Status:
Active, not recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Letrozole may prevent breast cancer in postmenopausal women with a BRCA1 or BRCA2
mutation.
PURPOSE: This randomized phase III trial is studying letrozole to see how well it works
compared with a placebo in preventing breast cancer in postmenopausal women with a BRCA1 or
BRCA2 mutation.